Barclays upgrades biotech stock it says can more than double

34451110 SS Hot sectors and majors med

Barclays thinks Relay Therapeutics stock can benefit from progress in drug tests to get a proposed breast cancer treatment approved, boosting the stock. The bank upgraded the biotechnology and drug discovery stock to overweight from equal weight on Friday, and reiterated a $15 per share price target. Barclays’ forecast implies more than 137% upside from Thursday’s $6.31 close. Relay stock has slumped 40% in 2024. RLAY YTD mountain Relay Therapeutics stock. Analyst Peter Lawson says there is a potential $4 billion market opportunity “for a mutant selective PI3Kalpha inhibitor” tied to treatments for HR+/HER2- breast cancer, or roughly 35% of the $12 billion in total sales in 2024 expected for “another class of drugs; CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) approved in HR+/HER2-.” “We believe the 2H update will help show the superior efficacy/safety profile for Relay’s PI3Kalpha (RLY-2608) over existing PI3Kalpha inhibitors like alpelisib and inavolisib,” Lawson said. “Based on our analysis of existing clinical data, we believe RLY-2608 has shown encouraging early data with clear signs of significant differentiation vs. existing molecules,” he added. Barclays sees a 70% chance of positive data emerging from an expanded Phase 1 study of RLY-2608 (+fulvestrant) in advanced HR+/HER2- breast cancer. That outcome, “all else equal, could potentially drive the stock up $5 while negative data could drive the stock down $2,” the bank said.

This article was originally published by a

Read it HERE


Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *